NYSE$CNC
Centene Corp · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Centene reported mixed results with revenue increase offset by a net loss, driven by divestiture-related charges and impairments. The company focused on portfolio optimization and capital deployment through share repurchases.
Centene Corporation reported a 9% increase in total revenues for Q4 2022, reaching $35.6 billion, driven by Medicaid and Medicare growth, and the acquisition of Magellan. However, the company experienced a GAAP diluted loss per share of $(0.38), while adjusted diluted EPS was $0.86. The company executed $1.4 billion in share repurchases during the quarter and increased its 2023 premium and service revenues guidance by $2.0 billion.
- Total revenues increased by 9% to $35.6 billion, driven by Medicaid and Medicare growth and the Magellan acquisition.
- GAAP diluted loss per share was $(0.38), while adjusted diluted EPS was $0.86.
- The company completed five divestitures in the past three months: Magellan Rx, Magellan Specialty Health, Ribera Salud, Centurion, and HealthSmart.
- Centene executed $1.4 billion of share repurchases in Q4 and increased its 2023 premium and service revenues guidance by $2.0 billion.
Headline financials
Revenue & EPS history
Centene · Revenue · Quarterly
$35.6B
Revenue by segment
Centene · $35.6B total across 4 segments · Q4 2022
- Medicaid$23.3B+8.4%65.6%
- Medicare$5.45B+24.2%15.3%
- Commercial$4.4B-3.6%12.4%
- Other$2.38B+14.0%6.7%
Forward guidance
Centene is increasing its 2023 premium and service revenues guidance range by $2.0 billion and reiterates its 2023 adjusted diluted EPS guidance of $6.25 to $6.40.
Tailwinds
- An additional $1.5 billion of Medicaid premium revenue reflecting a higher starting point in 2023 and an additional two months until redeterminations recommence on April 1, 2023.
- An additional $3.0 billion of Commercial premium revenue from a stronger than expected Marketplace open enrollment.
- The company reiterates its 2023 adjusted diluted EPS guidance of $6.25 to $6.40.
Headwinds
- Lower Medicare revenue of $500 million reflecting softer than expected 2023 annual enrollment.
- Decreased revenues of $2.0 billion reflecting the divestitures of Magellan Specialty Health, Centurion, and HealthSmart, which were completed in January 2023 and were previously included in our 2023 guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.4%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+1.9%
Avg return
30 days after
54%
37 / 68 earnings
Positive
+13.8%
Q1 2014
Best reaction
-10.4%
Q2 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.5% | +22.6% | +33.9% | |
| Q4 2025 | -3.7% | +1.3% | +9.3% | |
| Q3 2025 | +12.5% | +3.9% | +18.5% | |
| Q1 2025 | -6.3% | -2.8% | -8.4% | |
| Q4 2024 | -5.4% | -9.1% | -8.3% | |
| Q3 2024 | +0.0% | +0.3% | -2.0% | |
| Q2 2024 | +9.0% | +14.1% | +16.5% | |
| Q1 2024 | -2.4% | -4.5% | -1.4% | |
| Q4 2023 | +1.1% | +4.4% | +7.5% | |
| Q3 2023 | -3.0% | -4.8% | +4.7% | |
| Q2 2023 | -2.7% | -3.7% | -9.2% | |
| Q1 2023 | -1.5% | +1.9% | -6.3% | |
| Q4 2022 | +2.7% | +2.4% | -7.7% | |
| Q3 2022 | +11.9% | +13.2% | +10.3% | |
| Q2 2022 | +0.6% | +1.1% | +4.1% | |
| Q1 2022 | -4.9% | -5.1% | -3.5% | |
| Q4 2021 | +6.4% | +3.1% | +4.5% | |
| Q3 2021 | +3.8% | +4.8% | +11.2% | |
| Q2 2021 | -4.0% | -5.6% | -12.5% | |
| Q1 2021 | -9.9% | -6.5% | +11.7% | |
| Q4 2020 | +4.8% | +1.6% | +6.3% | |
| Q3 2020 | -7.9% | -11.0% | -6.3% | |
| Q2 2020 | -1.4% | -3.0% | -10.1% | |
| Q1 2020 | -6.6% | -8.3% | -5.5% | |
| Q4 2019 | +5.1% | +0.4% | -5.0% | |
| Q3 2019 | +5.7% | +5.4% | +30.4% | |
| Q2 2019 | +3.0% | +2.4% | -12.7% | |
| Q1 2019 | +4.4% | +9.5% | +15.3% | |
| Q4 2018 | -2.9% | -3.2% | -13.2% | |
| Q3 2018 | -8.3% | -9.9% | -5.5% | |
| Q2 2018 | -3.1% | -3.0% | +6.0% | |
| Q1 2018 | -1.2% | -0.4% | +5.5% | |
| Q4 2017 | +5.0% | +2.3% | +0.9% | |
| Q3 2017 | -7.4% | -3.7% | -1.1% | |
| Q2 2017 | -1.0% | -1.8% | +2.1% | |
| Q1 2017 | +1.1% | +3.3% | +4.5% | |
| Q4 2016 | +7.9% | +9.1% | +9.3% | |
| Q3 2016 | +1.4% | +0.1% | -10.5% | |
| Q2 2016 | -10.4% | -6.3% | -10.0% | |
| Q1 2016 | +4.2% | — | — | |
| Q4 2015 | +2.2% | — | — | |
| Q3 2015 | +5.3% | — | — | |
| Q2 2015 | +0.2% | — | — | |
| Q1 2015 | -9.7% | — | — | |
| Q4 2014 | +5.6% | — | — | |
| Q3 2014 | +9.3% | — | — | |
| Q2 2014 | +5.8% | — | — | |
| Q1 2014 | +13.8% | — | — | |
| Q4 2013 | +4.5% | — | — | |
| Q3 2013 | -4.1% | — | — | |
| Q2 2013 | +5.1% | — | — | |
| Q1 2013 | +4.4% | — | — | |
| Q4 2012 | +6.1% | — | — | |
| Q3 2012 | +0.3% | — | — | |
| Q2 2012 | +6.9% | — | — | |
| Q1 2012 | -6.0% | — | — | |
| Q4 2011 | -2.5% | — | — | |
| Q3 2011 | +12.6% | — | — | |
| Q2 2011 | +3.3% | — | — | |
| Q1 2010 | +10.9% | — | — | |
| Q1 2011 | +2.4% | — | — | |
| Q4 2008 | -6.5% | — | — | |
| Q4 2010 | -6.5% | — | — | |
| Q3 2009 | -6.6% | — | — | |
| Q2 2009 | -6.6% | — | — | |
| Q3 2010 | -6.6% | — | — | |
| Q4 2009 | -5.3% | — | — | |
| Q2 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro